Nexentis 在 Google Cloud 上部署了 MitoCareX Bio 的计算药物发现基础设施
Nexentis Technologies Inc. 宣布，其全资子公司 MitoCareX Bio 已在其 Google Cloud Platform 上部署计算药物发现基础设施，以增强计算能力、数据治理和运营灵活性。
为什么重要. MitoCareX Bio向Google Cloud的转型将支持其不断发展的药物发现需求，并使其计算能力与项目需求相匹配，有可能加快研究和开发进程。
深度阅读深度解读
01
影响到谁
- 1MitoCareX Bio
- ← 拥有事实
02
证据
- GGlobeNewswire public company news公司披露2026-10-07 19:32
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company.
- GGlobeNewswire public company news公司披露2026-10-07 19:32
The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
- GGlobeNewswire public company news公司披露2026-10-07 19:32
MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary
- GGlobeNewswire public company news公司披露2026-10-07 19:32
Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastru…
- GGlobeNewswire public company news公司披露2026-10-07 19:32
For example, the Company is using forward-looking statements when it discusses the anticipated benefits of deploying MitoCareX's computational drug discovery infrastructure on Google Cloud Platform, the expected enhancement of computational capacity, data governance and operatio…